Daniel Brennan

Chief Business and Operating Officer

Mr. Brennan most recently served as the Chief Commercial Officer at Catalyst Pharmaceuticals (NASDAQ: CPRX) and Chief Operating Officer at Edge Therapeutics (NASDAQ: EDGE) where he was responsible for pre-commercialization and launch activities of the company’s lead products targeting rare neurological conditions.  Previously, Mr. Brennan held several leadership positions at Lundbeck U.S., including Vice President and Group General Manager of Lundbeck’s U.S. Neurology Business Unit and Business Development group. Throughout his time in these positions, Lundbeck’s U.S. Neurology group launched four specialty orphan products and achieved growth in annual sales from $60 million to $820 million. Prior to Lundbeck, Mr. Brennan was at Abbott Laboratories, where he served as Divisional Vice President and General Management of the Acute Care Hospital Business Unit, which was responsible for more than 80 commercial personnel and over $240 million in hospital-based pharmaceutical sales. Mr. Brennan also served in various sales, marketing and new product development roles of increasing responsibility for Eli Lilly and Company from 1997 to 2007. Prior to joining Edge Therapeutics in late 2016, Mr. Brennan served as Chief Operating Officer and Executive Vice President of Insys Therapeutics for approximately 8 months.

Mr. Brennan received a B.A. degree in Psychology from the University of Notre Dame and an MBA degree, with distinction, from the Kellogg Graduate School of Business at Northwestern University.

NeuroTau, Inc. is a biotech company, formed in 2017, that focuses on developing drugs that target the disruption or decay of the important neurobiological protein called Tau

Contact Us

Close Bitnami banner